Organization | Grifols

Grifols Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4

Founded: Barcelona Spain (1940)

Organization Overview

First Clinical Trial

1999

NCT00606905

First Marketed Drug

1942

albumin (Human) (Plasbumin)

First NDA Approval

1942

albumin (Human) (Plasbumin)

Last Known Activity

2021

Timeline

NOW

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Active Ingredients

Marketed Drugs (16)

Key: Grifols (11) Acquired (5)

albumin (Human) (Plasbumin) (1942 NDA)

alpha-1 antitrypsin (Prolastin) (1987)

antihemophilic factor viii human (Hemofil M) (1974 NDA)

antithrombin iii (human) (thrombate iii) (1991 NDA)

fibrinogen (human) (RiaSTAP) (2017)

hepatitis b immune globulin (human) (BayHep B) (1977 NDA)

human coagulation factor ix (Mononine) (1990)

human factor ix complex (prothrombin complex concentrate) (Bebulin) (1981)

immune globulin (human) (Gamastan) (1944)

Plasma Protein Fraction (Human) (Plasmanate) (1958 NDA)

rabies immune globulin (human) (HyperRAB) (1974 NDA)

Rho(D) Immune Globulin Intravenous (Human) (WinRho) (1971 NDA)

sodium chloride (2017)

tetanus immunoglobulin (Bastet) (1957 NDA)

thrombin (bovine) (Thrombostat) (2017)

von Willebrand factor (Wilate) (1978 NDA)

Drugs in Phase 4 Trials (9)

Key: Grifols (5) Acquired (4)

albumin (Human) (Plasbumin) (21 trials)

antihemophilic factor viii human (Hemofil M) (6 trials)

antihemophilic factor viii (Recombinant) (Adynovate) (1 trial)

emicizumab (Hemlibra) (1 trial)

immune globulin (human) (Gamastan) (42 trials)

Tetanus and diphtheria toxoids adsorbed (Decavac) (2 trials)

tetanus immunoglobulin (Bastet) (1 trial)

von Willebrand factor (Wilate) (3 trials)

von Willebrand factor (recombinant) (Vonvendi) (3 trials)

Drugs in Phase 3 Trials (15)

Key: Grifols (10) Acquired (5)

alpha-1 antitrypsin (Prolastin) (16 trials)

antithrombin iii (human) (thrombate iii) (7 trials)

blood plasma (5 trials)

bt097 (1 trial)

ciprofloxacin (cipro) (2 trials)

covid 19 immune globulin (1 trial)

fibrinogen (human) (RiaSTAP) (5 trials)

glucose monohydrate (1 trial)

hepatitis b immune globulin (human) (BayHep B) (7 trials)

human fibrin (Tisseel) (4 trials)

IgM Concentrate (trimodulin) (3 trials)

naltrexone (revia) (1 trial)

sodium chloride (5 trials)

thrombin (human coagulation factor iia) (Evithrom) (2 trials)

thrombin (human coagulation factor iia) (Recombinant) (Recothrom) (1 trial)

Drugs in Phase 2 Trials (18)

Key: Grifols (6) Acquired (12)

abvac40 (2 trials)

aflibercept (zaltrap) (1 trial)

akst4290 (4 trials)

alk4290 (2 trials)

alteplase (Activase) (1 trial)

bt063 (1 trial)

coagulation factor ix (Recombinant) (Rixubis) (1 trial)

COVID-19 convalescent plasma (2 trials)

fibrinolysin, human (3 trials)

grf6021 (2 trials)

hepatitis c immune globulin (1 trial)

igm enriched immunoglobulins (2 trials)

indatuximab ravtansine (3 trials)

misoprostol (cytotec) (1 trial)

mometasone (elocon) (1 trial)

thrombin (bovine) (Thrombostat) (1 trial)

tregalizumab (3 trials)

urokinase (kinlytic) (1 trial)

Drugs in Phase 1 Trials (2)

Key: Grifols (1) Acquired (1)

giga-2050 (1 trial)

rabies immune globulin (human) (HyperRAB) (1 trial)

Drugs in Other Trials (1)

ringer's lactate (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Acquired Immunodeficiency Syndrome (Phase 3)

Acute Kidney Injury (Phase 4)

Acute-On-Chronic Liver Failure (Phase 3)

Afibrinogenemia (Phase 3)

Agammaglobulinemia (Phase 3)

alpha 1-Antitrypsin Deficiency (Phase 3)

Alzheimer Disease (Phase 3)

Amyloidosis (Phase 2)

Amyotrophic Lateral Sclerosis (Phase 2)

Antithrombin III Deficiency (Phase 3)

Arterial Occlusive Diseases (Phase 2)

Ascites (Phase 4)

Brain Diseases (Phase 2)

Bronchiectasis (Phase 3)

Common Variable Immunodeficiency (Phase 3)

Communicable Diseases (Phase 2)

Coronavirus Infections (Phase 2)

Crohn Disease (Phase 3)

Cystic Fibrosis (Phase 2)

Deficiency Diseases (Phase 4)

Diabetes Complications (Phase 2)

Diabetes Mellitus (Phase 2)

Diabetes Mellitus, Type 1 (Phase 2)

Diabetic Neuropathies (Phase 2)

Diphtheria (Phase 1)

Emphysema (Phase 3)

End Stage Liver Disease (Phase 3)

Epilepsy (Phase 3)

Fibrosis (Phase 4)

Hemophilia A (Phase 4)

Hemophilia B (Phase 2)

Hemorrhage (Phase 3)

Hepatic Encephalopathy (Phase 2)

Hepatic Insufficiency (Phase 3)

Hepatitis (Phase 4)

Hepatitis A (Phase 4)

Hepatitis B (Phase 3)

Hepatitis B, Chronic (Phase 3)

HIV Infections (Phase 3)

Hypotension (Phase 4)

IgG Deficiency (Phase 2)

Immunologic Deficiency Syndromes (Phase 4)

Infections (Phase 2)

Ischemia (Phase 2)

Liver Cirrhosis (Phase 4)

Liver Failure (Phase 3)

Lung Diseases, Obstructive (Phase 2)

Lupus Erythematosus, Cutaneous (Phase 1)

Lupus Erythematosus, Systemic (Phase 1)

Macular Degeneration (Phase 2)

Motor Neuron Disease (Phase 2)

Multiple Sclerosis (Phase 2)

Multiple Sclerosis, Relapsing-Remitting (Phase 2)

Muscle Weakness (Phase 4)

Muscular Diseases (Phase 2)

Myasthenia Gravis (Phase 4)

Peripheral Nervous System Diseases (Phase 2)

Poliomyelitis (Phase 3)

Polyneuropathies (Phase 3)

Polyradiculoneuropathy (Phase 3)

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (Phase 3)

Postpoliomyelitis Syndrome (Phase 3)

Postural Orthostatic Tachycardia Syndrome (Phase 2)

Pulmonary Disease, Chronic Obstructive (Phase 2)

Pulmonary Emphysema (Phase 3)

Purpura (Phase 3)

Purpura, Thrombocytopenic (Phase 3)

Purpura, Thrombocytopenic, Idiopathic (Phase 3)

Rabies (Phase 1)

Recurrence (Phase 4)

Sclerosis (Phase 2)

Severe Combined Immunodeficiency (Phase 3)

Shock (Phase 3)

Shock, Septic (Phase 3)

Stiff-Person Syndrome (Phase 3)

Stroke (Phase 2)

Syndrome (Phase 3)

Tachycardia (Phase 2)

Tetanus (Phase 4)

Tetany (Phase 4)

Thrombosis (Phase 2)

Venous Thrombosis (Phase 1)

von Willebrand Diseases (Phase 4)

Wiskott-Aldrich Syndrome (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 143
# of Trial APIs: 45